Lixte Biotechnology Holdings, Inc. · NASDAQ:LIXT
Lixte Biotechnology — Investor Presentation (December 2022)
20 slides from Lixte Biotechnology's investor presentation, Dec 6, 2022
Slide 1: LIXTE Biotechnology Holdings, Inc.
LIXTE Biotechnology Holdings, Inc. December 2022 LIXTE BIOTECHNOLOGY HOLDINGS, INC. Nasdaq: LIXT
Slide 2: Forward Looking Statements
Forward Looking Statements This information packet contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company’s financial position, business strateg
Slide 3: LIXTE - Dedicated to Creating Better Treatments for Cancer
LIXTE - Dedicated to Creating Better Treatments for Cancer * Clinical-stage drug discovery company. ¢ Using biomarker technology to identify enzyme targets associated with cancer and other serious common diseases, | and designing novel compounds ’ to attack those targets. Nasdaq: LIXT
Slide 4: Key Investment Considerations
Key Investment Considerations ¢ Unique, active, and less toxic compound, LB-100 is a first-in-class anti-cancer agent with no known competitors. ¢ LB-100 increases the anti-tumor activity of chemotherapy, radiotherapy and immunotherapy without increasing the toxicity. ¢ Potential total market for LB
Slide 5: LB-100: Game-Changing Discovery
LB-100: Game-Changing Discovery ° Rationale: Natural products with potent anti-PP2A activity (certain shellfish toxins) have | iS broad antitumor-activity in animal models but are ( 7 very toxic. N > ° PP2A is a master regulator of numerous cell O functions; it is known to be faulty and, thus, O sus
Slide 6: LB-100: Game-Changing Discovery
LB-100: Game-Changing Discovery Goal: Identify a potent and safe inhibitor of PP2A. Outcome: Developed LB-100 as a novel compound that is a potent inhibitor of enzyme PP2A, active against cancers in humans at non-toxic doses. LIXTE} Nasdaq: LIXT LB-100
Slide 7: LB-100: Unique, Active, Less Toxic Anti-Cancer Drug
LB-100: Unique, Active, Less Toxic Anti-Cancer Drug ¢ Multiple preclinical studies report that LB-100 increases the anti-tumor activity of: ¢ Chemotherapy * Radiotherapy ¢ Immunotherapy without increasing toxicity No known competitor to LB-100 in the market. Nasdaq: LIXT
Slide 8: Why LB-100 Works
Why LB-100 Works ° Basic cell activities require switches to rapidly turn on and turn off biochemical pathways for proper cell function. ¢ The major drivers of cancer are acquired defects in the switches. Nasdaq: LIXT
Slide 9: LB-100 inhibits a master off switch, PP2A
LB-100 inhibits a master “off switch,’ PP2A, that regulates many aspects of cell growth, repair of DNA damage, and regulation of T-cell immune function. Nasdaq: LIXT
Slide 10: Significant Breakthrough
Significant Breakthrough on” — . | ¢ Landmark Phase 1 clinical trial conducted and completed at Mayo Clinic, City of Hope, and US Oncology Network. ° Study showed LB-100 is well tolerated by cancer patients at doses associated with anti-cancer activity. Nasdaq: LIXT
Slide 11: Can LB-100 Improve Immune Therapy in General?
Can LB-100 Improve Immune Therapy in General? ¢ Studies in animals show that low doses of LB-100 enhance the effectiveness of immunotherapy of diverse cancer types by several mechanisms. ¢ Patients with PP2A inactivating mutations in their cancers respond exceptionally well to immunotherapy. PP2A in
Slide 12: New Opportunity: Demonstrate that LB-100 Enhances Immune Checkpoint Therapy
New Opportunity: Demonstrate that LB-100 Enhances Immune Checkpoint Therapy ° LB-100 lowers PP2A activity, and it may do so in many, if not all cancers, rendering these cancers more susceptible to immunotherapy. ° New trials are planned in the near future to determine if the addition of LB-100 is a
Slide 13: Strategy and Opportunities
Strategy and Opportunities ¢* Demonstrate that LB-100 markedly enhances chemotherapy and immunotherapy. ° Focus on aggressive tumors in which clinical benefit can be detected early after initiating treatment. ¢ Evaluate LB-100 in a number of cancers because extensive preclinical data indicate that L
Slide 14: Promising Clinical Trials Testing LB-100's Ability to Enhance Chemotherapy and Immunotherapy
Promising Clinical Trials Testing LB-100’s Ability to Enhance Chemotherapy and Immunotherapy LB-100 markedly improves standard anti-cancer therapy in animal models of two aggressive diseases. This has led to clinical trials in humans: * Small Cell Lung Cancer (SCLC) — Open and accruing patients ¢ Ad
Slide 15: Potential Impact of Current and Planned Clinical Trials
Potential Impact of Current and Planned Clinical Trials ° If LB-100 proves to enhance significantly the standard treatment with chemotherapy and immunotherapy for small cell lung cancer, it will be a long-awaited achievement in improving the outcome of patients with this very aggressive cancer. ¢ Si
Slide 16: The Distinguished LIXTE Team
The Distinguished LIXTE Team John S. Kovach, MD: Founder and CEO. Medical Oncologist and Clinical Pharmacologist; former director of NCI Comprehensive Cancer Centers at Mayo Clinic and City of Hope. James Miser, MD: Chief Medical Officer. Pediatric hematologist /oncologist, internationally recognize
Slide 17: Board of Directors
Board of Directors a = and i John S. Kovach, MD: Internationally recognized oncologist and former director of the cancer center at Mayo Clinic and City of Hope National Medical Center Prof. René Bernards: Leader in the field of molecular carcinogenesis at the Netherlands Cancer Institute in Amsterda
Slide 18: A Promising Future: Key Investment Highlights
A Promising Future: Key Investment Highlights ¢ LB-100 is a unique, active, well tolerated compound that has the potential to enhance cancer treatment without increasing toxicity. ¢ LB-100 may be effective in the treatment of particularly aggressive cancers where new treatments are urgently needed.
Slide 19: A Promising Future: Key Investment Highlights
A Promising Future: Key Investment Highlights ¢ LB-100 is a unique, active, well tolerated compound that has the potential to enhance cancer treatment without increasing toxicity. ¢ LB-100 may be effective in the treatment of particularly aggressive cancers where new treatments are urgently needed.
Slide 20: LIXTE Biotechnology Holdings, Inc.
LIXTE Biotechnology Holdings, Inc. LIXTE Biotechnology Holdings, Inc. 680 E Colorado Blvd., Suite 180 Pasadena, CA 91101 General Phone: (631) 830-7092 Investor Phone: (888) 289-5533 Fax: (631) 982-5050 info@lixte.com Nasdaa: LIXT
LIXTE Biotechnology Holdings — Investor Presentation (December 2022) on 6ix